Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.51 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 2/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 8/20 | 0.48 |
| ▸ | HTR1D | P28221 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1660061 | 0.91 | KCNA3 (0.56) | MCHR1KCNA3PDE5ATNFHTR1B | |
| SCHEMBL5449325 | 0.87 | KCNA3 (0.67) | MCHR1KCNA3PDE5AHTR1BHTR1D | |
| SCHEMBL11713358 | 0.87 | KCNA3 (0.47) | KCNA3TNFMAPT | |
| SCHEMBL14603570 | 0.84 | TNF (0.56) | KCNA3TNFHTR1BHTR1DMAPT | |
| SCHEMBL28985974 | 0.84 | HTR1B (0.65) | KCNA3TNFHTR1BHTR1DMAPT | |
| SCHEMBL6197255 | 0.80 | KCNA3 (0.47) | KCNA3TNFMAPT | |
| SCHEMBL2116954 | 0.79 | HTR1B (0.70) | KCNA3HTR1BHTR1DCNR1CNR2 | |
| SCHEMBL30209610 | 0.79 | HTR1B (0.70) | KCNA3HTR1BHTR1DCNR1CNR2 | |
| SCHEMBL1491286 | 0.78 | MAPT (0.56) | MCHR1TNFMAPT | |
| SCHEMBL21266927 | 0.76 | IKBKB (0.50) | KCNA3TNFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332917-B1 | Compounds for PIM kinase inhibition and for treating malignancy | SYGNIS BIOSCIENCE GMBH & CO KG (DE) | 2012-08-01 | — | — | EP | disclosed |
| EP-2332917-B1 | Compounds for PIM kinase inhibition and for treating malignancy | SYGNIS BIOSCIENCE GMBH & CO KG (DE) | 2012-08-01 | — | — | EP | disclosed |
| EP-2332917-A1 | Compounds for PIM kinase inhibition and for treating malignancy | Sygnis Bioscience GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | disclosed |
| EP-2332917-A1 | Compounds for PIM kinase inhibition and for treating malignancy | Sygnis Bioscience GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011057784-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011057784-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2011-05-19 | — | — | WO | disclosed |
| US-20100160297-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | AMNESTIX, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100160297-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | AMNESTIX, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100160297-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | AMNESTIX, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20070037846-A1 | Pyrazolidinedione derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-15 | — | — | US | disclosed |
| EP-1638540-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000281-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037846-A1 | Pyrazolidinedione derivatives | P2RY1, P2RY4, P2RY2 | MCHR1 3716/4885KCNA3 1080/4885PDE5A 435/4885 |
| US-20100160297-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | PIM1, PIM2, PIM3 | MCHR1 3842/4885KCNA3 4305/4885PDE5A 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.